Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Acta Biomater. 2019 Jan 30;87:140–151. doi: 10.1016/j.actbio.2019.01.062

Figure 6. Effect of ErbB2 inhibition on cardiac function with ECM treatment.

Figure 6.

Ventricle dilation at diastole (A) and systole (B) are no longer inhibited in ErbB2-inhibited mice treated with nmECM. (C) FAC and (D) EF are similar in all treatment groups when an ErbB2 inhibitor is administered at the time of MI. (E,F) Immunostaining of CD31+ and αSMA+ cells 6 weeks post-MI show similar numbers of blood vessels in all treatment groups after ErbB2 inhibition. (G,H) Immunostaining of CTnT+/Ki67+ in mice following ErbB2 inhibition shows similar numbers of proliferating cardiomyocytes 3 days post-MI regardless of treatment group (scale bar = 50μm; n = 4 per treatment group; p > 0.05 for all measurements).